title: Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats.
abstract: 1. Male, Sprague-Dawley rats were actively immunized with novel angiotensin vaccines, and their pressor responses to exogenous angiotensin I (AI) and angiotensin II (AII) were assessed in vivo. Serum antibody titres were also measured. 2. The most effective vaccine consisted of an AI analogue conjugated with a tetanus toxoid carrier protein and adjuvanted with aluminium hydroxide. When this vaccine was injected on days 0, 21 and 42, pressor responses to AI on day 63 were significantly inhibited (maximum, 8.9 fold shift), but responses to AII were unaffected. The anti-angiotensin antibody titre was increased 32,100 fold, and, uniquely, these antibodies also cross-reacted with angiotensinogen. 3. These findings indicate that active immunization against AI may be a useful approach for treating cardiovascular disorders involving the renin-angiotensin system.
authors.affiliation: School of Biomedical Sciences, Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK.
authors.forename: S M
authors.initials: SM
authors.lastname: Gardiner
authors.forename: T R
authors.initials: TR
authors.lastname: Auton
authors.forename: M R
authors.initials: MR
authors.lastname: Downham
authors.forename: H L
authors.initials: HL
authors.lastname: Sharp
authors.forename: P A
authors.initials: PA
authors.lastname: Kemp
authors.forename: J E
authors.initials: JE
authors.lastname: March
authors.forename: H
authors.initials: H
authors.lastname: Martin
authors.forename: P J
authors.initials: PJ
authors.lastname: Morgan
authors.forename: A
authors.initials: A
authors.lastname: Rushton
authors.forename: T
authors.initials: T
authors.lastname: Bennett
authors.forename: J F
authors.initials: JF
authors.lastname: Glover
mesh_terms: D000465:Algorithms; D000803:Angiotensin I / Q000031:analogs & derivatives / Q000276:immunology* / Q000494:pharmacology*; D000804:Angiotensin II / Q000031:analogs & derivatives / Q000276:immunology / Q000494:pharmacology; D000808:Angiotensinogen / Q000276:immunology / Q000494:pharmacology; D000818:Animals; D019138:Antibodies, Blocking / Q000032:analysis / Q000276:immunology; D001794:Blood Pressure / Q000187:drug effects* / Q000276:immunology*; D015153:Blotting, Western; D002352:Carrier Proteins / Q000276:immunology; D003429:Cross Reactions; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D014612:Vaccines / Q000276:immunology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D019138:Antibodies, Blocking; D002352:Carrier Proteins; D015842:Serine Proteinase Inhibitors; D014612:Vaccines; D014662:Vasoconstrictor Agents; D000808:Angiotensinogen; D000804:Angiotensin II; D000803:Angiotensin I